|Day Low/High||105.45 / 107.62|
|52 Wk Low/High||92.98 / 137.54|
The market is fearful. Use that fear to buy, Cramer says.
Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the 96-week blinded extension period (for a total of up to 120 weeks of exposure on treatment) of...
Celgene Corporation (NASDAQ: CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28 th as the first-ever Psoriatic Arthritis (PsA) Awareness Day—a day dedicated to raising public...
Celgene Corporation (NASDAQ:CELG) today announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and...
The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.
Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.
For patient Celgene investors, a very low-risk buying opportunity is developing.
So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
It's possible in light of VanEck Vectors Gold Miners ETF breaking down from a four-week trading range.
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.
Twelve-time Olympic medalist, best-selling author, host of a cable sports TV show, and mom Dara Torres dives into a very important conversation this summer as she teams up with Celgene Corporation (NASDAQ:CELG) and...
Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.
RBC Capital analysts say this would free 'trapped value' on drug treatments.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Celgene Corp. has taken over the #29 spot from Honeywell International Inc , according to ETF Channel.